期刊文献+

氯丙嗪与奎硫平对血脂和血糖的影响 被引量:6

The effect of chlorpromazine and quetiapine on serum lipid and glucose
下载PDF
导出
摘要 目的:研究氯丙嗪与奎硫平对精神分裂症患者血脂与血糖的影响。方法:130例精神分裂症患者随机分为氯丙嗪组(65例)与奎硫平组(65例),治疗8周。所有患者于治疗前与治疗4、8周测空腹血糖、总胆固醇、三酰甘油和体质量(体重)。结果:氯丙嗪组总胆固醇、三酰甘油、体质量在治疗第4、8周均较治疗前显著升高(P<0.01);奎硫平组三酰甘油、体质量在治疗第4、8周均较治疗前显著升高(P<0.01)。治疗8周后,两组男性患者总胆固醇与空腹血糖较治疗前均显著升高(P<0.01),女性患者三酰甘油与总胆固醇治疗后较治疗前显著升高(P<0.01)。结论:氯丙嗪与奎硫平对血脂和血糖的影响不同,2药对血脂与血糖的影响存在性别差异。 Objective: To study the effect of chlorpromazine and quetiapine on serum lipid and glucose in schizophrenia. Method: 130 patients with schizophrenia were divided into chlorpmmazine group( n = 65) and quetiapine group( n = 65) randomly for eight weeks. All the patients were measured fasting blood glucose, eholesteml, triglyceride and body weight before and after treatments for 4, 8 weeks. Results: After four-week and eight-week treatment, the concentrations of eholestorol triglyeeride and body weight ine^a.sed signifieantly in ehlorpmmazine group (P 〈 0.01).After four-week and eight-week treatment, the eoneentmtions of triglyeeride and body weight increased significantly in quetiapine group( P 〈 0.01 ). After eight-week treatment, the concentrations of cholesterol and glueoec increased markedly in male ( P 〈 0.01 ), and the concentrations of triglyeeride and cholesterol significantly increased in female ( P 〈 0.01 ). Conclusion: Chlorpromazine and quefiapine differ in their effect on serum lipid and glueoec. Gender differenees exist in effect of ehlorpmmazine and quefiapine on serum lipid and glueoec.
出处 《临床精神医学杂志》 2006年第5期257-259,共3页 Journal of Clinical Psychiatry
基金 "十五"国家科技攻关基金资助项目(2004BA720A22)
关键词 氯丙嗪 奎硫平 血脂 血糖 chlorpromazine quetiapine serum lipid serum glucose
  • 相关文献

参考文献7

二级参考文献50

  • 1刘燕,李华芳,王慧芳,王克勋,高哲石,顾牛范.氯氮平、利培酮对精神分裂症病人血糖-胰岛素稳态的影响及相关因素分析[J].上海精神医学,2003,15(5):257-259. 被引量:33
  • 2Harris M1, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose,and impaired glucose tolerance in U. S . adults.The Third National Health and Nutrition Examination Survey, 1988 -1994. Diabetes Care, 1998,21:518 - 524.
  • 3Henderson MD, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus,meight gain,and lipid abnormalities:a five-year naturalistic study. Am J Psychiatry,2000,157 (6) :975 -981.
  • 4Koller E, Schneider B, Bennett K, et al. Clozapine-associated diabetes. Am J Med,2001,111 (9) :716 -723.
  • 5Lindenmayer JP, Czobor P, Volavka J, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry,2003,162 (2) :290 - 296.
  • 6Semyak MJ, Leslie DL, Alarcon RD, et al. Association of diabetes mellitus with use of atypical neuroleptics in the treatment ofschizophrenia. Am J Psychiatry,2002,159(4) :561 - 566.
  • 7Wang PS,Glynn RJ,Gana DA,et al. Clozapine use and risk of diabetes mellitus. J Clin Psychopharmaco1,2002,22 (3) :236 - 243.
  • 8Komegay CJ, Vasilakis-Scaramozza C,Jick H. lncident diabetes associated with antlpsychotic use in the United Kingdom general practice research database. J Clin Psychiatry,2002,63 (9) :758 - 762.
  • 9Meyer JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone and olanzapine treated inpatients:metabolic outcomes after 1 year. Clin Psychiatry,2002,63 (5) :425 - 433.
  • 10Yamada J, Sugimoto Y, Yoshikawa T,et al. The involvement of the peripheral 5-HT2A receptor in peripherally administered serotonin-induced hyperglycemia in rats. Life Sci, 1995,57:819 - 825.

共引文献105

同被引文献54

引证文献6

二级引证文献43

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部